Maisonneuve, P., Agodoa, L., Gellert, R.J.H., Stewart, G., Buccianti, A.B., Lowenfels, R.A., Wolfe, E., Jones, A.P., Disney, D., Briggs, M., McCredie, P. and Boyle, P. (1999) Cancer in Patients on Dialysis for End-Stage Renal Disease: An International Collaborative Study. Lancet, 354, 93-99.
http://dx.doi.org/10.1016/S0140-6736(99)06154-1

has been cited by the following article:

• TITLE: Oxidative DNA Damage Is Elevated in Renal Patients Undergoing Haemodialysis

  AUTHORS: Twyla Moffitt, Florence Hariton, Megan Devlin, Peter J. Garrett, Mary P. A. Hannon-Fletcher

  KEYWORDS: Haemodialysis, Modified Comet Assay, Oxidative DNA Damage

  JOURNAL NAME: Open Journal of Preventive Medicine, Vol.4 No.6, June 11, 2014

  ABSTRACT: Background: End stage renal disease (ESRD) is associated with an increase in oxidative stress, cardiovascular disease and cancer. The main treatment for ESRD is haemodialysis (HD), which itself induces repetitive bouts of oxidative stress through membrane biocompatibility and endotoxin challenge. The resulting higher levels of reactive oxygen species in turn produce increased levels of oxidative DNA damage leading to genomic instability which may influence the higher risk of cancer reported in HD patients. Our aims were to measure levels of oxidative DNA damage in HD patients and in age and gender matched control volunteers. Methods: Thirty eight patients receiving HD in the Western Health and Social Services Trust (WHSCT) and 8 healthy volunteers were recruited. Volunteers gave informed consent and non-fasting morning blood samples were taken and assessed for DNA disruption using the comet assay modified to identify oxidative specific damage. Results: The HD patients had significantly elevated levels of alkaline DNA damage (19.46% ± 1.37% vs 3.86% ± 1.36% tail DNA, p